XTalks

JANUARY 28, 2022

Kimmtrak is part of a novel class of bispecific T cell immunotherapies being developed by Immunocore. Kimmtrak has also become the first bispecific T cell engager to be FDA-approved for the treatment of a solid tumor. Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

XTalks

AUGUST 17, 2020

Cue Biopharma is a Cambridge, Massachusetts-based clinical-stage biotechnology company that is focused on developing injectable immune biologics using its proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform. Cell-Based Immunotherapy vs. Immune Biologics. cells, receptors) to treat disease.

Protein 98

Protein Engineer Immune Response In-Vivo 98

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. CellCentric, a U.K-based

Development 52

Development Drugs Clinical Development Antibody 52

World of DTC Marketing

SEPTEMBER 7, 2022

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. More recently developed agents, such as CAR T-cell therapy, may cost almost USD 500,000 annually. Biogen’s failure should be a warning to other pharma companies.

Pharma Companies 210

Pharma Companies Marketing Drugs Production 210

Delveinsight

FEBRUARY 25, 2021

Beam employs three approaches to deliver its genetic medicines to cells. Electroporation is used for ex vivo delivery of therapies to blood and immune cells. The GuideTx technology screens for lipid nanoparticles inside the body that can be used to deliver RNA to cells throughout the body.

DNA 52

DNA In-Vivo Genetics Medicine 52

pharmaphorum

APRIL 5, 2022

Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – after getting a green light from the European Commission. It’s the first treatment for mUM in the EU, as well as the first BiTE drug to treat a solid tumour.

Protein 52

Protein Sales Drugs Trials 52

Drug Discovery World

MAY 22, 2023

Ryan Leahy , a science communication expert in cell and gene therapy, at Phacilitate, says there is a lot to celebrate but also much to assess, question and challenge in this sector. But are these price tags a barrier to access? million per dose.

Gene Therapy 52

Gene Therapy Gene Drugs Contamination 52

pharmaphorum

JANUARY 11, 2021

While bluebird has conducted pioneering work in gene therapy for blood disorders and in cancer cell therapy, products have been delayed by issues with filing data for the FDA. The gene therapy firm will be focused on its most important therapies in beta-thalassemia, cerebral adrenoleukodystrophy and sickle cell disease in the US And Europe.

Gene Therapy 58

Gene Therapy Gene Genetic Disease Manufacturing 58

The Pharma Data

MARCH 7, 2022

Researchers from the University of Washington School of Medicine in Seattle describe this finding in the journal Cell Reports. “The beauty of this approach is we can safely upregulate specific genes to affect cell activity without permanently changing the genome and cause unintended mistakes,” Levy said.

Protein 52

Protein Gene Genome Genomics 52

Delveinsight

FEBRUARY 9, 2021

Breyanzi, BMS’ Blood Cancer CAR-T Therapy Receives FDA Nod. Breyanzi targets CD19, a protein that is highly expressed on the surface of B cells, which remain there following the transformation of these cells from normal to malignant.

FDA Approval 52

FDA Approval Marketing Research Protein 52

The Pharma Data

MARCH 23, 2022

Their investigation reveals that an experimental drug that targets GSPT1 for degradation can also halt Ebola virus infection in human cells. who co-led the Cell Reports study with Scripps Research Professor Juan Carlos De La Torre, Ph.D., The team found that polymerase succeeds by biding its time in host cells.

Protein 52

Protein Genome Genomics Research 52

pharmaphorum

FEBRUARY 22, 2021

Last week, Bluebird said it was pausing its Zynteglo (betibeglogene autotemcel) programme in Europe after a phase 1/2 trial in patients with sickle cell disease (SCD) – another red blood cell disorder – turned up two cases of blood cancers, one of acute myeloid leukaemia (AML) and another of myelodysplastic syndrome (MDS).

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

World of DTC Marketing

DECEMBER 13, 2021

As cancer survival rates rise, so do the price tags of life-saving treatments. Cancers occur at the cellular level, with abnormal cells dividing and spreading. Why haven’t we invested more in prevention? Major cancer studies can’t be replicated . The post You can’t afford to get cancer.

Drugs 55

Drugs FDA Approval Medicine Containment 55

Drug Discovery World

JANUARY 30, 2024

I don’t think anyone disagrees that we need to bring down pricing to increase patient adoption and take strain off healthcare reimbursement systems. High-cost materials: Specialised equipment, reagents, and cell culture media significantly contribute to the overall cost.

Gene Therapy 71

Gene Therapy Manufacturing Gene Clinical Trials 71

pharmaphorum

JULY 25, 2022

Tecvayli (teclistamab) is an off-the-shelf bispecific antibody targeting both BCMA and CD3 which is also under review at the FDA and if approved will slot into J&J’s myeloma therapy portfolio alongside Darzalex (daratumumab) – an antibody directed at CD38 – and BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel).

Antibody 52

Antibody Medicine Drugs Trials 52

pharmaphorum

JANUARY 5, 2021

Like PD-L1, TIGIT is thought to act as a molecular brake that stops T cells from attacking tumours, and tiragolumab is currently leading the pack among drugs targeting the immune checkpoint. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Immune Response 52

Immune Response FDA Approval Drugs Sales 52

pharmaphorum

AUGUST 18, 2022

bluebird bio’s Zynteglo has become the first cell-based gene therapy to be approved in the US, getting the nod from the FDA as a treatment for patients with beta thalassaemia who require regular blood transfusions. bluebird has opted to launch it at a cost of $2.8 million, which compares to the $1.7

Gene Therapy 52

Gene Therapy FDA Approval Gene Clinical Trials 52

pharmaphorum

MAY 17, 2021

There had been speculation that the FDA might approve Empaveli (pegcetacoplan) only as a backup option for patients who don’t see a sufficient benefit with Alexion’s Soliris (eculizumab) or Ultomiris (ravulizumab), but the regulator opted for a broad indication that included first-line treatment for PNH. billion and $1.1

Drugs 52

Drugs FDA Approval Marketing Clinical Trials 52

Drug Discovery World

NOVEMBER 9, 2023

Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’. Gail Calvert, Field Application Scientist, Sartorius UK, on: ‘Leveraging integrated and advanced technologies for successful cell line development’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

pharmaphorum

NOVEMBER 16, 2022

This is the case for the new generation of treatments known as advanced therapies, which encompasses cell and gene therapies, as well as tissue engineering. Of the innovations that have happened recently in pharma drug development, it is cell and gene therapy that have received the most attention. However, with a price tag of €1.58

Gene Therapy 126

Gene Therapy Gene Marketing Development 126

pharmaphorum

MARCH 27, 2022

Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU the next few weeks, after getting a green light from the EMA’s human medicines committee. The post CHMP backs J&J’s myeloma CAR-T therapy Carvykti appeared first on.

Antibody 84

Antibody Clinical Trials Clinical Trials Sales 84

XTalks

JANUARY 19, 2024

Therapeutic radiopharmaceuticals deliver beta or alpha radiation, which destroys diseased cells, such as cancer cells. The aim of these compounds is to deliver radiation directly to the tumor cells, minimizing damage to surrounding healthy tissues. Anderson, PharmD, PhD, Radiation Clinical Pharmacologist, A.

DNA 66

DNA Radiology FDA Approval Development 66

pharmaphorum

DECEMBER 2, 2020

These plans were soon abandoned and Hospira has remained a key part of the core Pfizer organisation – but that didn’t put the idea of separate business units to rest completely. For all the latest Pfizer news follow pharmaphorum’s Pfizer tag. The post A history of Pfizer appeared first on.

Sales 127

Sales Production Drugs Marketing 127

Drug Discovery World

NOVEMBER 13, 2023

Alexander Yermanos, PhD, Lecturer, Systems & Synthetic Immunology, ETH Zurich, on: ‘Integrating single-cell immune repertoire sequencing, machine learning, and biophysical properties of antibodies’. He will discuss selection technologies for membrane targets using advances in whole cell panning and comparative deep sequencing.

Protein 59

Protein Antibody Engineer Scientist 59

pharmaphorum

AUGUST 26, 2022

Roctavian delivers a working copy of the Factor VIII gene into cells via an adeno-associated virus (AAV) vector, and offers a one-shot, potentially curative therapy for haemophilia A. For now, the list price hasn’t been set and will depend on discussions with reimbursement authorities, according to the biotech.

Gene Therapy 109

Gene Therapy Gene Antibody Marketing 109

Roots Analysis

AUGUST 28, 2022

Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry.

Genome 52

Genome Genomics RNA Genome Project 52

Drug Discovery World

OCTOBER 21, 2022

Take, for example, its use for CD4 T cell counting to facilitate HIV monitoring. Flow cytometry is a technique used to rapidly analyse single cells in order to characterise their physical, chemical and biological properties. . Overview, evolution, trends .

Reagent 52

Reagent Antibody Drugs Protein 52

The Pharma Data

MAY 13, 2021

Which is one of the only ingredients ever scientifically proven to lower cortisol and block Adamts1’s conversion of stem cells into fat cells. After all, the ingredients we’ve chosen to include in Spade SB-66 are premium ingredients and come with a hefty price tag. And the mechanism behind fat cell differentiation is well known.

Packaging 52

Packaging Packaging Containment Production 52

The Pharma Data

MAY 15, 2021

Maybe I’m just old-fashioned but I still believe that you shouldn’t have to pay for something if it’s not a fit for you. Most people don’t know it, but U.S Please don’t think I am crazy but this is freaking amazing. Please don’t think I am crazy but this is freaking amazing.

Production 52

Production Containment Medicine Vaccination 52

The Pharma Data

MAY 5, 2021

Athenex shares soar with buyout of natural killer T cell player ( Endpoints ). AbbVie’s Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along ( Fierce ). . The weird science of the placebo effect keeps getting more interesting ( Vox ).

Vaccination 52

Vaccination Vaccine Gene Therapy Contract Packaging 52